权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow

昆虫药物：明天的抗炎药物

基本信息

批准号：
8124051
负责人：
ANDREW D ROBERTSON
金额：
$ 0.84万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-03-01 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8124051
关键词：
Academia Address Adopted Anti-Inflammatory Agents Anti-inflammatory Asthma Basic Science Clinic Clinical Clinical Trials Collaborations Development Discipline Disease Drug usage Environmental Risk Factor Evolution Fostering Future Generations Genes Genome Grant Health Healthcare Human Human Genome Immune Immune system Immunology Incidence Industry Inflammatory Inflammatory Bowel Diseases Knowledge Laboratories Location Magic Mediating Mentors Methodology Outcome Patients Pharmaceutical Preparations Request for Proposals Research Research Personnel Scientist Staging Stream Technology Therapeutic Training Utah Viral Work career clinical practice drug development drug discovery expectation improved insight man meetings novel novel strategies novel therapeutics pathogen pressure research and development success symposium therapeutic development trend

项目摘要

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow, organized by Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard, which will be held in Snowbird, Utah from April 3 - 7, 2011. A recent global trend is that fewer novel therapeutics are progressing from the pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. The Keystone Symposia meeting on Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a wellspring for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations directed at the generation of new drug strategies for the future. Opportunities for interdisciplinary interactions will be significantly enhanced by the co-location of this meeting with the Keystone Symposia meeting on Evolving Approaches to Early-Stage Drug Discovery. PUBLIC HEALTH RELEVANCE: Advances in drug discovery technology have raised expectations that the global drug development industry will deliver "magic bullets" or "wonder drugs" for a range of diseases, in particular inflammatory disorders. In fact, fewer novel therapeutics are progressing from the pipeline to the clinic, and the lack of new treatments is a growing health concern due to the worldwide increase in the incidence of a range of many diseases, such as asthma and inflammatory bowel disease. The Keystone Symposia meeting on Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach.

描述（由申请人提供）：本提案要求支持由Padraic G.组织的题为“来自错误的药物：明天的抗炎药物”的Keystone研讨会会议。作者声明：by Fallon，Grant McFadden，and阿曼达E.I. Proudfoot Fichard，将于2011年4月3日至7日在犹他州雪鸟举行。最近的一个全球趋势是，越来越少的新疗法正在从管道进入临床。这促使药物研究和开发部门在扩大寻找新药方面采取不那么传统的方法。Keystone研讨会上的药物从错误：明天的抗炎药会议将审查越来越多的机会，发现新的药物从病原体，或“药物从错误”的方法。人类基因组是人类适应环境因素进化的产物，传染性病原体施加了强大的选择压力。当今一些主要的免疫介导的疾病与进化为对病原体作出反应的基因有关。通过了解病原体如何调节和篡夺免疫系统，以及通过识别病原体的功能分子，可以开发新的治疗策略和新药。事实上，新一代病原体衍生的免疫调节分子现在正在临床试验中。在这次会议上，领先的专家将介绍病原体作为新疗法源泉的使用现状。该论坛将为业界提供一个与学术界合作的机会，以制定药物发现的新策略。这次会议将汇集跨学科的科学家交流和分享想法，从而促进合作，为未来的新药物战略的产生。跨学科互动的机会将显着提高本次会议的共同地点与Keystone研讨会会议上不断发展的方法，以早期阶段的药物发现。公共卫生相关性：药物发现技术的进步提高了人们的期望，即全球药物开发行业将为一系列疾病，特别是炎症性疾病提供“灵丹妙药”或“特效药”。事实上，越来越少的新疗法正在从管道走向临床，由于全球范围内许多疾病（如哮喘和炎症性肠病）的发病率增加，缺乏新的治疗方法是一个日益严重的健康问题。基石研讨会会议的药物从错误：抗炎药物的明天将审查越来越多的机会，发现新的药物从病原体，或“药物从错误”的方法。